Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study

Study conducted at The Massachusetts General Hospital’s Vaccine and Immunotherapy Center demonstrated highly significant improvements in Overall Survival and other key endpoints 

As seen previously, VTX-067 produced a safety profile similar to that seen in the Control group 

NEW YORK, July 14, 2022 – Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that data from the previously announced Study ‘098 demonstrated clear Proof-of Concept for VTX-067 in the treatment of HPV related cancers. This is a well-validated murine model of HPV related cancers.  

VTX-067, a Self-Assembling Vaccine (SAV) targeting select peptides from HPV related cancers, was developed using Voltron’s Self Assembling Vaccine Platform.  Voltron has executed an exclusive worldwide license for this technology from The Massachusetts General Hospital’s (MGH) Vaccine and Immunotherapy Center (VIC). 

Study ‘098 was a double blind, preclinical study evaluating VTX-067 in TC-1 tumor injected mice to evaluate its impact on Overall Survival of the mice, as well as other key efficacy and safety endpoints.  The Primary Endpoint of the study was the vaccine’s impact on Overall Survival of the mice. 

Results of the study demonstrated: 

  • Improved Overall Survival: VTX-067/SAV had a highly significant, positive survival effect in the TC-1 tumor injected mice 
  • Tumor volume reduction: VTX-067 significantly reduced TC-1 tumor volume  
  • Dose response: there was a clear dose-response to SAV, with the overall best survival benefit to the TC-1 tumor bearing mice at the highest dose of SAV.  
  • Safety Profile: the SAV construct once again demonstrated it is well tolerated with no observed reactogenicity.  

Commented Dr. Mark Poznansky, Director, Vaccine and Immunotherapy Center, MGH: “The data clearly demonstrate that the inclusion of highly immunogenic epitopes derived from HPV in our self-assembled vaccine significantly controlled tumor growth and augmented survival in a well-established mouse model of HPV induced cancer, in comparison to control animals treated with saline or immunogenic peptides. Treatment with our vaccine also generated significant HPV targeted cell mediated immunity with no detectable reactogenicity. These results met, and indeed exceeded, our expectations for efficacy and immunogenicity in this important model”. 

Patrick J. Gallagher, Voltron’s Chief Executive Officer commented, “We are tremendously excited about the results of this rigorously designed, double blind study for many reasons.  First, our vaccine eradicated tumors in a number of mice in this aggressive tumor model at higher doses.  Second, the data once again supports the SAV’s incredible flexibility: Voltron has demonstrated success in producing a significant immune response in 4 different disease/animal models by using between 2 and 11 disease specific peptides.  Finally, we have gained additional confidence in the utility of combing the SAV with a PD-1 inhibitor to drive targeted, durable responses.” 

James Ahern, Managing Partner, Laidlaw & Company (UK) and Founder of Lucius Partners, stated, “The team’s expertise and commitment to driving this proof-of-concept study forward with a view to first in human trials has produced compelling results.  We continue to identify additional programs for Voltron, which we will pursue in both oncology and infectious disease, that leverage our highly flexible vaccine platform to create new solutions for clinicians and patients.  We remain focused on de-risking our programs and to provide value to our shareholders.” 


About Voltron Therapeutics, Inc. 

Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital’s novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and Emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and development team, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (including Lassa Fever) as well as two oncology indications (Ovarian and HPV Related Cancers). For more information, please visit www.voltrontx.com. 


About Lucius Partners, LLC 

Lucius Partners is a consultancy that provides a broad suite of services to help healthcare companies grow, achieve milestones and generate value for their shareholders. 


Forward Looking Statements 

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron’s current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law. 



Patrick Gallagher, CEO 

Voltron Therapeutics, Inc. 

Managing Partner 

Lucius Partners, LLC 



Matthew Duffy, President 

Voltron Therapeutics, Inc.  

Managing Partner 

Lucius Partners, LLC